#prasad — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #prasad, aggregated by home.social.
-
https://www.europesays.com/people/68324/ Trump FDA chief is leaving after angering pharma CEOs, vaping lobbyists and anti-abortion groups #agency #AntiAbortionGroup #DonaldTrumpJr #DrugAdministration #FDA #FdaCommissioner #FdaDrugReview #food #makary #medicine #prasad #PresidentTrump #SafetyVaccine #SpecialtyDrugmaker #staff #Trump #year
-
creates semantic nodes and clusters #WILL #LEWIS #AUSTRALIAN #FOOTBALLER advanced-search.headlines-world.com/advanced-sea... #AHUTI #PRASAD allgraph.ro/advanced-sea... Do you like aéPiot semantics? Donate to the aéPiot semantic platform: www.paypal.com/donate?busin...
MultiSearch Tag Explorer -
creates semantic nodes and clusters #WILL #LEWIS #AUSTRALIAN #FOOTBALLER advanced-search.headlines-world.com/advanced-sea... #AHUTI #PRASAD allgraph.ro/advanced-sea... Do you like aéPiot semantics? Donate to the aéPiot semantic platform: www.paypal.com/donate?busin...
MultiSearch Tag Explorer -
creates semantic nodes and clusters 1935 IN #NORWAY headlines-world.com/advanced-sea... #JAI #NARAIN #PRASAD #NISHAD semantic-search.allgraph.ro/advanced-sea... Do you like aéPiot semantics? Donate to the aéPiot semantic platform: www.paypal.com/donate?busin...
MultiSearch Tag Explorer -
creates semantic nodes and clusters 1935 IN #NORWAY headlines-world.com/advanced-sea... #JAI #NARAIN #PRASAD #NISHAD semantic-search.allgraph.ro/advanced-sea... Do you like aéPiot semantics? Donate to the aéPiot semantic platform: www.paypal.com/donate?busin...
MultiSearch Tag Explorer -
#GAYA #PRASAD #PAL semantic-search.aepiot.com/advanced-sea... #LINDSAY #ELLINGSON www.perplexity.ai/search/new?q... opentip.kaspersky.com/aepiot.com/ aePiot: Inspire your growth with Web 4.0. Construct nodes and rule SEO.
MultiSearch Tag Explorer -
#GAYA #PRASAD #PAL semantic-search.aepiot.com/advanced-sea... #LINDSAY #ELLINGSON www.perplexity.ai/search/new?q... opentip.kaspersky.com/aepiot.com/ aePiot: Inspire your growth with Web 4.0. Construct nodes and rule SEO.
MultiSearch Tag Explorer -
#MATA #PRASAD advanced-search.allgraph.ro/advanced-sea... #BATTLE OF #MANDORA search.brave.com/ask?q=Analyz... www.paypal.com/donate?busin... aePiot: Bridge to Web 4.0. Construct nodes. Own SEO.
MultiSearch Tag Explorer -
#MATA #PRASAD advanced-search.allgraph.ro/advanced-sea... #BATTLE OF #MANDORA search.brave.com/ask?q=Analyz... www.paypal.com/donate?busin... aePiot: Bridge to Web 4.0. Construct nodes. Own SEO.
MultiSearch Tag Explorer -
The Trump administration is considering #Houman #Hemmati, an ophthalmologist, entrepreneur and frequent Fox News guest,
to serve as the nation’s next top regulator of #vaccines and treatments for complex diseasesIf selected, Hemmati would replace #Vinay #Prasad, who is slated to leave the high-ranking position at the Food and Drug Administration at the end of April
after a rocky year.Prasad had overseen controversial decisions about drugs and a new plan to tighten vaccine approvals, which drew condemnation from former agency leaders.
Prasad was briefly forced out last summer after just three months on the job.
He was reinstated less than two weeks later with the help of vaccine critic Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary.Hemmati, if given the job, would arrive amid scrutiny from the White House on FDA operations.
Concerns over the agency’s direction mounted late last year as leadership turned over,
rattling the drug industry,
which relies on a predictable FDA to understand what it needs to do to win approvals for new treatments.Hemmati has served in various industry roles,
including top medical positions at Optigo Biotherapeutics,
which focuses on treatments for neovascular and degenerative retinal diseases,
and Vyluma, a company developing eye drops.He has worked as an adjunct clinical assistant professor at USC’s Keck School of Medicine, according to his LinkedIn profile.
Hemmati’s outspoken skepticism of the federal government’s response to the coronavirus pandemic helped win him fans,
including Makary and then-Stanford professor Jay Bhattacharya
— who now hold senior roles in the Trump administration.
Hemmati, who has said he was forced to flee Iran with his family as a child, also has supported President Donald Trump’s efforts for regime change in the country, expressing support for the American military in a TV appearance last month and on social media.In 2023, Hemmati questioned why the federal government should be paying for more coronavirus vaccines.
He praised a new approach to the coronavirus vaccine that Prasad outlined last year, which narrowed approval for updated shots to older adults and people with at least one health condition. -- In past years, shots had been broadly recommended, including to children and generally healthy adults
-
The Trump administration is considering #Houman #Hemmati, an ophthalmologist, entrepreneur and frequent Fox News guest,
to serve as the nation’s next top regulator of #vaccines and treatments for complex diseasesIf selected, Hemmati would replace #Vinay #Prasad, who is slated to leave the high-ranking position at the Food and Drug Administration at the end of April
after a rocky year.Prasad had overseen controversial decisions about drugs and a new plan to tighten vaccine approvals, which drew condemnation from former agency leaders.
Prasad was briefly forced out last summer after just three months on the job.
He was reinstated less than two weeks later with the help of vaccine critic Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary.Hemmati, if given the job, would arrive amid scrutiny from the White House on FDA operations.
Concerns over the agency’s direction mounted late last year as leadership turned over,
rattling the drug industry,
which relies on a predictable FDA to understand what it needs to do to win approvals for new treatments.Hemmati has served in various industry roles,
including top medical positions at Optigo Biotherapeutics,
which focuses on treatments for neovascular and degenerative retinal diseases,
and Vyluma, a company developing eye drops.He has worked as an adjunct clinical assistant professor at USC’s Keck School of Medicine, according to his LinkedIn profile.
Hemmati’s outspoken skepticism of the federal government’s response to the coronavirus pandemic helped win him fans,
including Makary and then-Stanford professor Jay Bhattacharya
— who now hold senior roles in the Trump administration.
Hemmati, who has said he was forced to flee Iran with his family as a child, also has supported President Donald Trump’s efforts for regime change in the country, expressing support for the American military in a TV appearance last month and on social media.In 2023, Hemmati questioned why the federal government should be paying for more coronavirus vaccines.
He praised a new approach to the coronavirus vaccine that Prasad outlined last year, which narrowed approval for updated shots to older adults and people with at least one health condition. -- In past years, shots had been broadly recommended, including to children and generally healthy adults
-
The Trump administration is considering #Houman #Hemmati, an ophthalmologist, entrepreneur and frequent Fox News guest,
to serve as the nation’s next top regulator of #vaccines and treatments for complex diseasesIf selected, Hemmati would replace #Vinay #Prasad, who is slated to leave the high-ranking position at the Food and Drug Administration at the end of April
after a rocky year.Prasad had overseen controversial decisions about drugs and a new plan to tighten vaccine approvals, which drew condemnation from former agency leaders.
Prasad was briefly forced out last summer after just three months on the job.
He was reinstated less than two weeks later with the help of vaccine critic Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary.Hemmati, if given the job, would arrive amid scrutiny from the White House on FDA operations.
Concerns over the agency’s direction mounted late last year as leadership turned over,
rattling the drug industry,
which relies on a predictable FDA to understand what it needs to do to win approvals for new treatments.Hemmati has served in various industry roles,
including top medical positions at Optigo Biotherapeutics,
which focuses on treatments for neovascular and degenerative retinal diseases,
and Vyluma, a company developing eye drops.He has worked as an adjunct clinical assistant professor at USC’s Keck School of Medicine, according to his LinkedIn profile.
Hemmati’s outspoken skepticism of the federal government’s response to the coronavirus pandemic helped win him fans,
including Makary and then-Stanford professor Jay Bhattacharya
— who now hold senior roles in the Trump administration.
Hemmati, who has said he was forced to flee Iran with his family as a child, also has supported President Donald Trump’s efforts for regime change in the country, expressing support for the American military in a TV appearance last month and on social media.In 2023, Hemmati questioned why the federal government should be paying for more coronavirus vaccines.
He praised a new approach to the coronavirus vaccine that Prasad outlined last year, which narrowed approval for updated shots to older adults and people with at least one health condition. -- In past years, shots had been broadly recommended, including to children and generally healthy adults
-
The Trump administration is considering #Houman #Hemmati, an ophthalmologist, entrepreneur and frequent Fox News guest,
to serve as the nation’s next top regulator of #vaccines and treatments for complex diseasesIf selected, Hemmati would replace #Vinay #Prasad, who is slated to leave the high-ranking position at the Food and Drug Administration at the end of April
after a rocky year.Prasad had overseen controversial decisions about drugs and a new plan to tighten vaccine approvals, which drew condemnation from former agency leaders.
Prasad was briefly forced out last summer after just three months on the job.
He was reinstated less than two weeks later with the help of vaccine critic Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary.Hemmati, if given the job, would arrive amid scrutiny from the White House on FDA operations.
Concerns over the agency’s direction mounted late last year as leadership turned over,
rattling the drug industry,
which relies on a predictable FDA to understand what it needs to do to win approvals for new treatments.Hemmati has served in various industry roles,
including top medical positions at Optigo Biotherapeutics,
which focuses on treatments for neovascular and degenerative retinal diseases,
and Vyluma, a company developing eye drops.He has worked as an adjunct clinical assistant professor at USC’s Keck School of Medicine, according to his LinkedIn profile.
Hemmati’s outspoken skepticism of the federal government’s response to the coronavirus pandemic helped win him fans,
including Makary and then-Stanford professor Jay Bhattacharya
— who now hold senior roles in the Trump administration.
Hemmati, who has said he was forced to flee Iran with his family as a child, also has supported President Donald Trump’s efforts for regime change in the country, expressing support for the American military in a TV appearance last month and on social media.In 2023, Hemmati questioned why the federal government should be paying for more coronavirus vaccines.
He praised a new approach to the coronavirus vaccine that Prasad outlined last year, which narrowed approval for updated shots to older adults and people with at least one health condition. -- In past years, shots had been broadly recommended, including to children and generally healthy adults
-
The Trump administration is considering #Houman #Hemmati, an ophthalmologist, entrepreneur and frequent Fox News guest,
to serve as the nation’s next top regulator of #vaccines and treatments for complex diseasesIf selected, Hemmati would replace #Vinay #Prasad, who is slated to leave the high-ranking position at the Food and Drug Administration at the end of April
after a rocky year.Prasad had overseen controversial decisions about drugs and a new plan to tighten vaccine approvals, which drew condemnation from former agency leaders.
Prasad was briefly forced out last summer after just three months on the job.
He was reinstated less than two weeks later with the help of vaccine critic Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary.Hemmati, if given the job, would arrive amid scrutiny from the White House on FDA operations.
Concerns over the agency’s direction mounted late last year as leadership turned over,
rattling the drug industry,
which relies on a predictable FDA to understand what it needs to do to win approvals for new treatments.Hemmati has served in various industry roles,
including top medical positions at Optigo Biotherapeutics,
which focuses on treatments for neovascular and degenerative retinal diseases,
and Vyluma, a company developing eye drops.He has worked as an adjunct clinical assistant professor at USC’s Keck School of Medicine, according to his LinkedIn profile.
Hemmati’s outspoken skepticism of the federal government’s response to the coronavirus pandemic helped win him fans,
including Makary and then-Stanford professor Jay Bhattacharya
— who now hold senior roles in the Trump administration.
Hemmati, who has said he was forced to flee Iran with his family as a child, also has supported President Donald Trump’s efforts for regime change in the country, expressing support for the American military in a TV appearance last month and on social media.In 2023, Hemmati questioned why the federal government should be paying for more coronavirus vaccines.
He praised a new approach to the coronavirus vaccine that Prasad outlined last year, which narrowed approval for updated shots to older adults and people with at least one health condition. -- In past years, shots had been broadly recommended, including to children and generally healthy adults
-
FDA's Vinay Prasad, controversial CBER chief, to depart
https://misryoum.com/us/trending/fdas-vinay-prasad-controversial-cber-chief-to-depart/
WASHINGTON — Vinay Prasad, a top official at the Food and Drug Administration who has been at the center of recurring public controversies, is exiting the agency for a second time. Prasad will leave the FDA at the end of...
#FDAs #Vinay #Prasad #controversial #CBER #chief #depart #US_News_Hub #misryoum_com
-
The U.S. Food and Drug Administration is
refusing to consider Moderna’s application for a new flu vaccine
made with Nobel Prize-winning mRNA technology.The news is the latest sign of the FDA’s heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr.,
particularly those using mRNA technology,
which he has criticized before and after becoming the nation’s top health official.Moderna received what’s called a “refusal-to-file” letter from the FDA
that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.
That trial concluded the new vaccine was somewhat more effective in adults 50 and older than that standard shot.The letter from FDA vaccine director Dr. #Vinay #Prasad said the agency doesn’t consider the application to contain an
“adequate and well-controlled trial”
because it didn’t compare the new shot to “the best-available standard of care in the United States at the time of the study.”
Prasad’s letter pointed to some advice FDA officials gave Moderna in 2024, under the Biden administration, which Moderna didn’t followAccording to Moderna, that feedback said it was acceptable to use the standard-dose flu shot the company had chosen
— but that another brand specifically recommended for seniors would be preferred for anyone 65 and older in the study.Still, Moderna said, the FDA did agree to let the study proceed as originally planned
The company said it also had shared with FDA additional data from a separate trial
comparing the new vaccine against a licensed high-dose shot used for seniors.The FDA “did not identify any safety or efficacy concerns with our product”
and “does not further our shared goal of enhancing America’s leadership in developing innovative medicines,”
Moderna CEO Stephane Bancel said in a statement.
https://apnews.com/article/moderna-vaccine-flu-mrna-2fc551cb2fb45735e67db0a4e2e2b0fb -
The U.S. Food and Drug Administration is
refusing to consider Moderna’s application for a new flu vaccine
made with Nobel Prize-winning mRNA technology.The news is the latest sign of the FDA’s heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr.,
particularly those using mRNA technology,
which he has criticized before and after becoming the nation’s top health official.Moderna received what’s called a “refusal-to-file” letter from the FDA
that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.
That trial concluded the new vaccine was somewhat more effective in adults 50 and older than that standard shot.The letter from FDA vaccine director Dr. #Vinay #Prasad said the agency doesn’t consider the application to contain an
“adequate and well-controlled trial”
because it didn’t compare the new shot to “the best-available standard of care in the United States at the time of the study.”
Prasad’s letter pointed to some advice FDA officials gave Moderna in 2024, under the Biden administration, which Moderna didn’t followAccording to Moderna, that feedback said it was acceptable to use the standard-dose flu shot the company had chosen
— but that another brand specifically recommended for seniors would be preferred for anyone 65 and older in the study.Still, Moderna said, the FDA did agree to let the study proceed as originally planned
The company said it also had shared with FDA additional data from a separate trial
comparing the new vaccine against a licensed high-dose shot used for seniors.The FDA “did not identify any safety or efficacy concerns with our product”
and “does not further our shared goal of enhancing America’s leadership in developing innovative medicines,”
Moderna CEO Stephane Bancel said in a statement.
https://apnews.com/article/moderna-vaccine-flu-mrna-2fc551cb2fb45735e67db0a4e2e2b0fb -
The U.S. Food and Drug Administration is
refusing to consider Moderna’s application for a new flu vaccine
made with Nobel Prize-winning mRNA technology.The news is the latest sign of the FDA’s heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr.,
particularly those using mRNA technology,
which he has criticized before and after becoming the nation’s top health official.Moderna received what’s called a “refusal-to-file” letter from the FDA
that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.
That trial concluded the new vaccine was somewhat more effective in adults 50 and older than that standard shot.The letter from FDA vaccine director Dr. #Vinay #Prasad said the agency doesn’t consider the application to contain an
“adequate and well-controlled trial”
because it didn’t compare the new shot to “the best-available standard of care in the United States at the time of the study.”
Prasad’s letter pointed to some advice FDA officials gave Moderna in 2024, under the Biden administration, which Moderna didn’t followAccording to Moderna, that feedback said it was acceptable to use the standard-dose flu shot the company had chosen
— but that another brand specifically recommended for seniors would be preferred for anyone 65 and older in the study.Still, Moderna said, the FDA did agree to let the study proceed as originally planned
The company said it also had shared with FDA additional data from a separate trial
comparing the new vaccine against a licensed high-dose shot used for seniors.The FDA “did not identify any safety or efficacy concerns with our product”
and “does not further our shared goal of enhancing America’s leadership in developing innovative medicines,”
Moderna CEO Stephane Bancel said in a statement.
https://apnews.com/article/moderna-vaccine-flu-mrna-2fc551cb2fb45735e67db0a4e2e2b0fb -
The U.S. Food and Drug Administration is
refusing to consider Moderna’s application for a new flu vaccine
made with Nobel Prize-winning mRNA technology.The news is the latest sign of the FDA’s heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr.,
particularly those using mRNA technology,
which he has criticized before and after becoming the nation’s top health official.Moderna received what’s called a “refusal-to-file” letter from the FDA
that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.
That trial concluded the new vaccine was somewhat more effective in adults 50 and older than that standard shot.The letter from FDA vaccine director Dr. #Vinay #Prasad said the agency doesn’t consider the application to contain an
“adequate and well-controlled trial”
because it didn’t compare the new shot to “the best-available standard of care in the United States at the time of the study.”
Prasad’s letter pointed to some advice FDA officials gave Moderna in 2024, under the Biden administration, which Moderna didn’t followAccording to Moderna, that feedback said it was acceptable to use the standard-dose flu shot the company had chosen
— but that another brand specifically recommended for seniors would be preferred for anyone 65 and older in the study.Still, Moderna said, the FDA did agree to let the study proceed as originally planned
The company said it also had shared with FDA additional data from a separate trial
comparing the new vaccine against a licensed high-dose shot used for seniors.The FDA “did not identify any safety or efficacy concerns with our product”
and “does not further our shared goal of enhancing America’s leadership in developing innovative medicines,”
Moderna CEO Stephane Bancel said in a statement.
https://apnews.com/article/moderna-vaccine-flu-mrna-2fc551cb2fb45735e67db0a4e2e2b0fb -
The U.S. Food and Drug Administration is
refusing to consider Moderna’s application for a new flu vaccine
made with Nobel Prize-winning mRNA technology.The news is the latest sign of the FDA’s heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr.,
particularly those using mRNA technology,
which he has criticized before and after becoming the nation’s top health official.Moderna received what’s called a “refusal-to-file” letter from the FDA
that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.
That trial concluded the new vaccine was somewhat more effective in adults 50 and older than that standard shot.The letter from FDA vaccine director Dr. #Vinay #Prasad said the agency doesn’t consider the application to contain an
“adequate and well-controlled trial”
because it didn’t compare the new shot to “the best-available standard of care in the United States at the time of the study.”
Prasad’s letter pointed to some advice FDA officials gave Moderna in 2024, under the Biden administration, which Moderna didn’t followAccording to Moderna, that feedback said it was acceptable to use the standard-dose flu shot the company had chosen
— but that another brand specifically recommended for seniors would be preferred for anyone 65 and older in the study.Still, Moderna said, the FDA did agree to let the study proceed as originally planned
The company said it also had shared with FDA additional data from a separate trial
comparing the new vaccine against a licensed high-dose shot used for seniors.The FDA “did not identify any safety or efficacy concerns with our product”
and “does not further our shared goal of enhancing America’s leadership in developing innovative medicines,”
Moderna CEO Stephane Bancel said in a statement.
https://apnews.com/article/moderna-vaccine-flu-mrna-2fc551cb2fb45735e67db0a4e2e2b0fb -
FDA finally admits COVID-19 vaccine killed kids: 'This is a profound revelation'
-
FDA finally admits COVID-19 vaccine killed kids: 'This is a profound revelation'
-
Rekha’s ‘Umrao Jaan’ Among 10 Restored Indian Classics Showcased by Prasad at Goa Festival (EXCLUSIVE)
#Variety #Asia #Global #MarketsFestivals #News #IFFI #Prasad #Rekha #UmraoJaan -
Rekha’s ‘Umrao Jaan’ Among 10 Restored Indian Classics Showcased by Prasad at Goa Festival (EXCLUSIVE)
#Variety #Asia #Global #MarketsFestivals #News #IFFI #Prasad #Rekha #UmraoJaan -
Rekha’s ‘Umrao Jaan’ Among 10 Restored Indian Classics Showcased by Prasad at Goa Festival (EXCLUSIVE)
#Variety #Asia #Global #MarketsFestivals #News #IFFI #Prasad #Rekha #UmraoJaan -
Rekha’s ‘Umrao Jaan’ Among 10 Restored Indian Classics Showcased by Prasad at Goa Festival (EXCLUSIVE)
#Variety #Asia #Global #MarketsFestivals #News #IFFI #Prasad #Rekha #UmraoJaan -
Rekha’s ‘Umrao Jaan’ Among 10 Restored Indian Classics Showcased by Prasad at Goa Festival (EXCLUSIVE)
#Variety #Asia #Global #MarketsFestivals #News #IFFI #Prasad #Rekha #UmraoJaan -
Rekha’s ‘Umrao Jaan’ Among 10 Restored Indian Classics Showcased by Prasad at Goa Festival (EXCLUSIVE)
-
He noted that snippets of #Prasad’s comments still appeared on #antivaccine social media accounts, suggesting Prasad was directing his removal demand only at a critic and not anti-vaccine influencers. In the past, Prasad has complained about censorship by social media companies.” (2/2)
-
He noted that snippets of #Prasad’s comments still appeared on #antivaccine social media accounts, suggesting Prasad was directing his removal demand only at a critic and not anti-vaccine influencers. In the past, Prasad has complained about censorship by social media companies.” (2/2)
-
He noted that snippets of #Prasad’s comments still appeared on #antivaccine social media accounts, suggesting Prasad was directing his removal demand only at a critic and not anti-vaccine influencers. In the past, Prasad has complained about censorship by social media companies.” (2/2)
-
He noted that snippets of #Prasad’s comments still appeared on #antivaccine social media accounts, suggesting Prasad was directing his removal demand only at a critic and not anti-vaccine influencers. In the past, Prasad has complained about censorship by social media companies.” (2/2)
-
He noted that snippets of #Prasad’s comments still appeared on #antivaccine social media accounts, suggesting Prasad was directing his removal demand only at a critic and not anti-vaccine influencers. In the past, Prasad has complained about censorship by social media companies.” (2/2)
-
https://www.theguardian.com/us-news/2025/aug/31/fda-official-youtube-videos?CMP=Share_iOSApp_Other ““It’s really important to remember [#Prasad’s] past words in order to gauge his current and future credibility, and that was the mission of my YouTube channel, to record what these doctors [Prasad and others] said,” Howard said.
Although the videos Howard collected were often only viewed “dozens” of times, Howard included them in his online articles that appeared on the #ScienceBasedMedicine blog. Now those video links are dead. (1/2)
-
https://www.theguardian.com/us-news/2025/aug/31/fda-official-youtube-videos?CMP=Share_iOSApp_Other ““It’s really important to remember [#Prasad’s] past words in order to gauge his current and future credibility, and that was the mission of my YouTube channel, to record what these doctors [Prasad and others] said,” Howard said.
Although the videos Howard collected were often only viewed “dozens” of times, Howard included them in his online articles that appeared on the #ScienceBasedMedicine blog. Now those video links are dead. (1/2)
-
https://www.theguardian.com/us-news/2025/aug/31/fda-official-youtube-videos?CMP=Share_iOSApp_Other ““It’s really important to remember [#Prasad’s] past words in order to gauge his current and future credibility, and that was the mission of my YouTube channel, to record what these doctors [Prasad and others] said,” Howard said.
Although the videos Howard collected were often only viewed “dozens” of times, Howard included them in his online articles that appeared on the #ScienceBasedMedicine blog. Now those video links are dead. (1/2)
-
https://www.theguardian.com/us-news/2025/aug/31/fda-official-youtube-videos?CMP=Share_iOSApp_Other ““It’s really important to remember [#Prasad’s] past words in order to gauge his current and future credibility, and that was the mission of my YouTube channel, to record what these doctors [Prasad and others] said,” Howard said.
Although the videos Howard collected were often only viewed “dozens” of times, Howard included them in his online articles that appeared on the #ScienceBasedMedicine blog. Now those video links are dead. (1/2)
-
https://www.theguardian.com/us-news/2025/aug/31/fda-official-youtube-videos?CMP=Share_iOSApp_Other ““It’s really important to remember [#Prasad’s] past words in order to gauge his current and future credibility, and that was the mission of my YouTube channel, to record what these doctors [Prasad and others] said,” Howard said.
Although the videos Howard collected were often only viewed “dozens” of times, Howard included them in his online articles that appeared on the #ScienceBasedMedicine blog. Now those video links are dead. (1/2)
-
Trump White House Cites Fringe Doctor to Defend Research Cuts
UCSF professor Vinay Prasad emerges as rationalizer-in-chief for Trump’s NIH cuts
https://www.importantcontext.news/p/trump-white-house-cites-fringe-doctor
-
Trump White House Cites Fringe Doctor to Defend Research Cuts
UCSF professor Vinay Prasad emerges as rationalizer-in-chief for Trump’s NIH cuts
https://www.importantcontext.news/p/trump-white-house-cites-fringe-doctor
-
Trump White House Cites Fringe Doctor to Defend Research Cuts
UCSF professor Vinay Prasad emerges as rationalizer-in-chief for Trump’s NIH cuts
https://www.importantcontext.news/p/trump-white-house-cites-fringe-doctor
-
Trump White House Cites Fringe Doctor to Defend Research Cuts
UCSF professor Vinay Prasad emerges as rationalizer-in-chief for Trump’s NIH cuts
https://www.importantcontext.news/p/trump-white-house-cites-fringe-doctor
-
Trump White House Cites Fringe Doctor to Defend Research Cuts
UCSF professor Vinay Prasad emerges as rationalizer-in-chief for Trump’s NIH cuts
https://www.importantcontext.news/p/trump-white-house-cites-fringe-doctor
-
The many doctors who are just now realizing that misinformation wasn't
"COVID hysteria nonsense"
have a lot of catching up to do to understand how the forces they've legitimized led to this moment.When he’s not busy spreading Orwellian doublespeak, saying less money is more money,
Dr. Vinay Prasad is busy celebrating cuts to researchers,
as well as mass purges of scientists and the ascension of RFK Jr.Dr. #Prasad, along with his friends and ideological compatriots
Drs. Jay #Bhattacharya and Marty #Makary, are now the embodiment of the medical establishment,
and their vision is being realized.They wanted RFK Jr. to “disrupt the US medical establishment”
and that’s what he’s doing.Anyone who either legitimized these doctors or defended them by baselessly smearing their critics contributed to this moment.
-
The many doctors who are just now realizing that misinformation wasn't
"COVID hysteria nonsense"
have a lot of catching up to do to understand how the forces they've legitimized led to this moment.When he’s not busy spreading Orwellian doublespeak, saying less money is more money,
Dr. Vinay Prasad is busy celebrating cuts to researchers,
as well as mass purges of scientists and the ascension of RFK Jr.Dr. #Prasad, along with his friends and ideological compatriots
Drs. Jay #Bhattacharya and Marty #Makary, are now the embodiment of the medical establishment,
and their vision is being realized.They wanted RFK Jr. to “disrupt the US medical establishment”
and that’s what he’s doing.Anyone who either legitimized these doctors or defended them by baselessly smearing their critics contributed to this moment.
-
The many doctors who are just now realizing that misinformation wasn't
"COVID hysteria nonsense"
have a lot of catching up to do to understand how the forces they've legitimized led to this moment.When he’s not busy spreading Orwellian doublespeak, saying less money is more money,
Dr. Vinay Prasad is busy celebrating cuts to researchers,
as well as mass purges of scientists and the ascension of RFK Jr.Dr. #Prasad, along with his friends and ideological compatriots
Drs. Jay #Bhattacharya and Marty #Makary, are now the embodiment of the medical establishment,
and their vision is being realized.They wanted RFK Jr. to “disrupt the US medical establishment”
and that’s what he’s doing.Anyone who either legitimized these doctors or defended them by baselessly smearing their critics contributed to this moment.
-
The many doctors who are just now realizing that misinformation wasn't
"COVID hysteria nonsense"
have a lot of catching up to do to understand how the forces they've legitimized led to this moment.When he’s not busy spreading Orwellian doublespeak, saying less money is more money,
Dr. Vinay Prasad is busy celebrating cuts to researchers,
as well as mass purges of scientists and the ascension of RFK Jr.Dr. #Prasad, along with his friends and ideological compatriots
Drs. Jay #Bhattacharya and Marty #Makary, are now the embodiment of the medical establishment,
and their vision is being realized.They wanted RFK Jr. to “disrupt the US medical establishment”
and that’s what he’s doing.Anyone who either legitimized these doctors or defended them by baselessly smearing their critics contributed to this moment.
